Le Lézard
Classified in: Health
Subject: ACC

Enzymatica - Publication of the Annual Report 2019


STOCKHOLM, April 2, 2020 /PRNewswire/ -- Enzymatica announces today that the annual report 2019 is available on the company's web site www.enzymatica.se. The annual report is produced in Swedish. A brief English version of the annual report is available on the English version of the website.https://www.enzymatica.se/investerare/finansiella-rapporter/ or https://www.enzymatica.se/en/investors/financial-reports/

About Enzymatica AB

Enzymatica AB is a Swedish life science company that develops and sells health care products for primarily conditions of the ear-nose-and-throat region. The products are based on a barrier technology that includes marine enzymes. The company's first product is the medical device ColdZyme®, a mouth spray against common cold. The product has been launched in about ten markets. The strategy is to continue to grow by developing more health care products and strengthening the company's position in existing markets and expanding into new geographic markets through established partners. The company has its headquarters in Lund and is listed on Nasdaq First North Growth Market. For more information, visit: www.enzymatica.com and www.enzymatica.se/en/section/media/press-releases

Enzymatica's certified adviser is Erik Penser Bank. Phone: +46-(0)8-463-83-00. Email: [email protected]

Enzymatica AB Ideon Science Park, SE-223 70 Lund, Sweden Telefon +46-46-286-31 00

For more information, please contact:
Fredrik Lindberg
CEO Enzymatica AB
Phone: +46-(0)708-86-53-70 
Email: [email protected] 

Carl-Johan Wachtmeister
Communication manager Enzymatica AB
Phone: +46-(0)701-50-21 
Email: [email protected]

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/enzymatica-ab/r/enzymatica---publication-of-the-annual-report-2019,c3079326

The following files are available for download:

https://mb.cision.com/Main/18091/3079326/1222785.pdf

Release

 


These press releases may also interest you

at 22:03
The report titled "Anti-Mullerian Hormone Test Market by Product (POC Testing, Self-check Kits), End-User (Commercial Labs, Research & development), Distribution, Use - Global Forecast 2024-2030" is now available on 360iResearch.com's offering,...

at 20:40
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

at 19:40
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

at 19:05
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

at 19:00
David J. Dykeman, co-chair of the Life Sciences & Medical...

at 18:30
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...



News published on and distributed by: